164 related articles for article (PubMed ID: 18285440)
41. Surrogate endpoints in randomized cardiovascular clinical trials.
Domanski M; Pocock S; Bernaud C; Borer J; Geller N; Revkin J; Zannad F
Fundam Clin Pharmacol; 2011 Aug; 25(4):411-3. PubMed ID: 20698890
[TBL] [Abstract][Full Text] [Related]
42. [Drug-eluting stents for diabetic patients. A critical appraisal of the currently available data from randomized trials].
Silber S; Herdeg C
Herz; 2008 Apr; 33(3):196-205. PubMed ID: 18568314
[TBL] [Abstract][Full Text] [Related]
43. Taxanes alone or in combination with anthracyclines as first-line therapy of patients with metastatic breast cancer.
Piccart-Gebhart MJ; Burzykowski T; Buyse M; Sledge G; Carmichael J; Lück HJ; Mackey JR; Nabholtz JM; Paridaens R; Biganzoli L; Jassem J; Bontenbal M; Bonneterre J; Chan S; Basaran GA; Therasse P
J Clin Oncol; 2008 Apr; 26(12):1980-6. PubMed ID: 18421049
[TBL] [Abstract][Full Text] [Related]
44. Surrogate end points in clinical research: hazardous to your health.
Grimes DA; Schulz KF
Obstet Gynecol; 2005 May; 105(5 Pt 1):1114-8. PubMed ID: 15863552
[TBL] [Abstract][Full Text] [Related]
45. Biomarkers in Alzheimer's disease: not yet surrogate endpoints.
Coley N; Andrieu S; Delrieu J; Voisin T; Vellas B
Ann N Y Acad Sci; 2009 Oct; 1180():119-24. PubMed ID: 19906266
[TBL] [Abstract][Full Text] [Related]
46. Statistical evaluation of surrogate endpoints with examples from cancer clinical trials.
Buyse M; Molenberghs G; Paoletti X; Oba K; Alonso A; Van der Elst W; Burzykowski T
Biom J; 2016 Jan; 58(1):104-32. PubMed ID: 25682941
[TBL] [Abstract][Full Text] [Related]
47. Potential surrogate endpoints in cancer research--some considerations and examples.
Duffy SW; Treasure FP
Pharm Stat; 2011; 10(1):34-9. PubMed ID: 20029937
[TBL] [Abstract][Full Text] [Related]
48. Odds ratio for 2 × 2 tables: Mantel-Haenszel estimator, profile likelihood, and presence of surrogate responses.
Banerjee B; Biswas A
J Biopharm Stat; 2014; 24(3):649-59. PubMed ID: 24697719
[TBL] [Abstract][Full Text] [Related]
49. Sufficient conditions for concluding surrogacy based on observed data.
Wu Z; He P; Geng Z
Stat Med; 2011 Aug; 30(19):2422-34. PubMed ID: 21590703
[TBL] [Abstract][Full Text] [Related]
50. Surrogate threshold effect: an alternative measure for meta-analytic surrogate endpoint validation.
Burzykowski T; Buyse M
Pharm Stat; 2006; 5(3):173-86. PubMed ID: 17080751
[TBL] [Abstract][Full Text] [Related]
51. Disability as an outcome in MS clinical trials.
Ebers GC; Heigenhauser L; Daumer M; Lederer C; Noseworthy JH
Neurology; 2008 Aug; 71(9):624-31. PubMed ID: 18480462
[TBL] [Abstract][Full Text] [Related]
52. Reporting of time-to-event end points and tracking of failures in randomized trials of radiotherapy with or without any concomitant anticancer agent for locally advanced head and neck cancer.
Le Tourneau C; Michiels S; Gan HK; Siu LL
J Clin Oncol; 2009 Dec; 27(35):5965-71. PubMed ID: 19805677
[TBL] [Abstract][Full Text] [Related]
53. Magnitude of benefit of adjuvant chemotherapy for non-small cell lung cancer: meta-analysis of randomized clinical trials.
Bria E; Gralla RJ; Raftopoulos H; Cuppone F; Milella M; Sperduti I; Carlini P; Terzoli E; Cognetti F; Giannarelli D
Lung Cancer; 2009 Jan; 63(1):50-7. PubMed ID: 18565615
[TBL] [Abstract][Full Text] [Related]
54. Does hormone treatment added to radiotherapy improve outcome in locally advanced prostate cancer?: meta-analysis of randomized trials.
Bria E; Cuppone F; Giannarelli D; Milella M; Ruggeri EM; Sperduti I; Pinnarò P; Terzoli E; Cognetti F; Carlini P
Cancer; 2009 Aug; 115(15):3446-56. PubMed ID: 19484790
[TBL] [Abstract][Full Text] [Related]
55. Evaluating and adjusting for premature censoring of progression-free survival.
Rothmann M; Koti K; Lee KY; Lu HL; Shen YL; Zhang JJ; Jin M; Zhou H
J Biopharm Stat; 2013; 23(5):1091-105. PubMed ID: 23957518
[TBL] [Abstract][Full Text] [Related]
56. Association between the N-terminally truncated (DeltaN) p63alpha (DeltaNp63alpha) isoform and debulking status, VEGF expression and progression-free survival in previously untreated, advanced stage epithelial ovarian cancer: A Gynecologic Oncology Group study.
Jewell EL; Darcy KM; Hutson A; Lee PS; Havrilesky LJ; Grace LA; Berchuck A; Secord AA
Gynecol Oncol; 2009 Dec; 115(3):424-9. PubMed ID: 19767063
[TBL] [Abstract][Full Text] [Related]
57. Larynx preservation clinical trial design: key issues and recommendations-a consensus panel summary.
Lefebvre JL; Ang KK;
Int J Radiat Oncol Biol Phys; 2009 Apr; 73(5):1293-303. PubMed ID: 19306746
[TBL] [Abstract][Full Text] [Related]
58. Survival end point reporting in randomized cancer clinical trials: a review of major journals.
Mathoulin-Pelissier S; Gourgou-Bourgade S; Bonnetain F; Kramar A
J Clin Oncol; 2008 Aug; 26(22):3721-6. PubMed ID: 18669458
[TBL] [Abstract][Full Text] [Related]
59. The role of maintenance chemotherapy in advanced nonsmall cell lung cancer.
Jalal SI; Ademuyiwa FO; Hanna NH
Curr Opin Oncol; 2009 Mar; 21(2):110-5. PubMed ID: 19532011
[TBL] [Abstract][Full Text] [Related]
60. Biological surrogate end-points in cancer trials: potential uses, benefits and pitfalls.
Cooper R; Kaanders JH
Eur J Cancer; 2005 Jun; 41(9):1261-6. PubMed ID: 15939261
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
